Back to Prevention

Who Should Avoid Tenofovir Alafenamide?

Who Should Avoid Tenofovir Alafenamide?
Bareback Guide 6 May 2026

Tenofovir alafenamide suits a wide range of people and is specifically useful where the older tenofovir is not. The situations where it is unsuitable are defined and generally have a straightforward alternative.

Who cannot take it?

Anyone with severe kidney impairment, where the threshold depends on the specific product. It is usable at levels of reduced function where the older form would not be, which is one of its main advantages, but it is not suitable at the lowest levels of function.

What about dialysis?

Some products have been studied in people on haemodialysis and others have not. This is a specialist decision and not one to generalise from a leaflet. Anyone in that situation will have their regimen chosen by a team familiar with it.

Who is excluded by interactions?

Anyone taking rifampicin or rifapentine for tuberculosis, since these reduce alafenamide levels enough to risk treatment failure. The same applies to strong enzyme-inducing anticonvulsants such as carbamazepine and phenytoin, and to St John's wort.

Who should think carefully about the metabolic effects?

Anyone with substantial cardiovascular risk: existing high cholesterol, diabetes, high blood pressure, a family history of early heart disease. The lipid profile is less favourable than with the older tenofovir, and for some people that outweighs the kidney and bone advantages.

What about weight?

Not a contraindication, and a legitimate consideration. Someone who has gained significant weight on an alafenamide-based regimen, particularly one also containing an integrase inhibitor, may reasonably ask about switching. This is a conversation to have rather than something to accept silently.

What about hepatitis B?

Not a reason to avoid it, and often a reason to choose it, since it treats both. What it does mean is that stopping cannot be casual, because abrupt withdrawal can cause a liver flare. Any stopping must be planned and monitored.

What about pregnancy?

Data have accumulated and are broadly reassuring, and the older tenofovir has a longer and larger safety record, which is why it is sometimes preferred. Anyone pregnant or planning a pregnancy should discuss it rather than stopping or switching independently.

What about severe liver disease?

Not recommended in severe hepatic impairment, where it has not been adequately studied. Mild to moderate impairment generally does not require adjustment.

What is the closest alternative?

Tenofovir disoproxil, the older form, which delivers the same active drug with a different balance of effects: harder on kidneys and bones, better for lipids and weight, and considerably cheaper. Switching between them is straightforward.

What alternatives avoid tenofovir entirely?

Two-drug regimens such as dolutegravir with lamivudine, or dolutegravir with rilpivirine, both established options for suitable people. Abacavir-based combinations for anyone without the HLA-B*5701 gene variant. Which is appropriate depends on resistance history, hepatitis status and what else you take.

What about long-acting options?

For treatment, injectable cabotegravir with rilpivirine every two months, for people already suppressed. For prevention, injectable cabotegravir or lenacapavir where available. These remove daily tablets entirely and require reliable attendance at appointments.

Is switching between the two forms difficult?

No. It is a common and straightforward change, usually made by moving to a different single-tablet regimen. Viral suppression is maintained through the switch provided the rest of the regimen remains active.

What should you tell your clinic?

Any kidney or bone problem, your cardiovascular risk factors, recent weight changes, and everything you take. The choice between tenofovir forms is genuinely a trade-off, and it can only be made well with an accurate picture.

What if it is the only option available?

Rarely the case. HIV medicine now has enough options that almost every situation has an alternative, and where choices genuinely are limited a specialist will construct something around your resistance profile. Being told there is nothing else is worth a second opinion.

Who decides?

You do, with a clinician. Suitability is a clinical judgement and the choice between suitable options is yours, including on grounds like convenience, appearance of tablets or how a schedule fits your life. Those are legitimate reasons rather than trivial ones.